RxDoctor Payments Data

Barbara Bishop

Neurology · Virginia Beach, VANPI 1588736946

Payments from drug & device makers

$12,133in general payments, 2019–2025

Across 518 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Sanofi$983
  • UCB, Inc.$627
  • Biogen$614
  • plus $6K from 42 others

What the payments were for

  • Consulting fees$1,0509%
  • Travel & lodging$2382%
  • Food & beverage$10,08983%
  • Education$7566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,133 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$94,180
Medicare patients
392
Services billed
5,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab42$375,405
Nurtec OdtRimegepant Sulfate50$88,641
AptiomEslicarbazepine Acetate44$70,358
Emgality PenGalcanezumab-Gnlm74$68,901
FingolimodFingolimod Hcl16$60,908
Teriflunomide111$52,485
BriviactBrivaracetam23$30,919
Glatiramer Acetate15$26,001
RytaryCarbidopa/Levodopa11$15,424
Aimovig AutoinjectorErenumab-Aooe18$13,320
Memantine Hcl303$13,168
Emgality SyringeGalcanezumab-Gnlm12$12,832
QuliptaAtogepant11$12,631
Dalfampridine ErDalfampridine38$11,926
Carbamazepine ErCarbamazepine56$6,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$128$93,04468 claims
Sunovion Pharmaceuticals Inc.Aptiom$106$70,35844 claims
UCB, Inc.Briviact$627$30,91923 claims
Amneal Pharmaceuticals LLCRytary$140$15,42411 claims
AbbVieQulipta$1,253$12,63111 claims
Upsher-smith Laboratories LLCTopiramate$42$2,671149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 neurology providers in Virginia.

Other neurology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →